Recommendation of the President – Citrulline 200, Citrulline 1000, L-Citrulline
On 31 October 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 113/2024 on the legitimacy of granting approval for the reimbursement of the products Citrulline 200, Citrulline 1000, L-Citrulline for the indications: ornithine transcarbamylase deficiency, carbamylphosphate synthase 1 deficiency, lysinuric protein intolerance